Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management

JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Long non-coding RNAs in prostate cancer: Functional roles and clinical implications

YH Xu, JL Deng, G Wang, YS Zhu - Cancer letters, 2019 - Elsevier
Long noncoding RNAs (lncRNAs) are defined as RNA transcripts longer than 200
nucleotides that do not encode proteins. LncRNAs have been documented to exhibit …

Raman spectroscopy in prostate cancer: techniques, applications and advancements

F Gaba, WJ Tipping, M Salji, K Faulds, D Graham… - Cancers, 2022 - mdpi.com
Simple Summary Raman spectroscopic analysis is a promising and powerful optical
investigative tool to interrogate tissue and/or biofluids for in vitro and in vivo applications …

68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?

T Lengana, IO Lawal, TG Boshomane… - Clinical genitourinary …, 2018 - Elsevier
Purpose 68 Ga ligands targeting prostate-specific membrane antigen (PSMA) are rapidly
emerging as a significant step forward in the management of prostate cancer. PSMA is a …

Clinically localized prostate cancer: AUA/ASTRO/SUO guideline

MG Sanda, RC Chen, T Crispino, S Freedland… - Risk, 2017 - auajournals.org
Purpose Following a prostate cancer diagnosis, patients are faced with a multitude of care
options, the advisability of which is influenced by patient factors and by cancer severity or …

Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma

S Xu, XM Yi, CP Tang, JP Ge… - Oncology …, 2016 - spandidos-publications.com
Long non-coding RNAs (lncRNAs) have been identified to be critical mediators in various
tumors associated with cancer progression. Long non-coding RNA activated by TGF-β …

Deep convolutional neural networks combine Raman spectral signature of serum for prostate cancer bone metastases screening

X Shao, H Zhang, Y Wang, H Qian, Y Zhu… - … , Biology and Medicine, 2020 - Elsevier
Prostate cancer most frequently metastasizes to bone, resulting in abnormal bone
metabolism and the release of components into the blood stream. Here, we evaluated the …

Cost‐effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer

CL Barnett, MS Davenport, JS Montgomery… - BJU …, 2018 - Wiley Online Library
Objective To determine how best to use magnetic resonance imaging (MRI) and targeted
MRI/ultrasonography fusion biopsy for early detection of prostate cancer (PCa) in men with …

ACR Appropriateness Criteria® prostate cancer—pretreatment detection, surveillance, and staging

FV Coakley, A Oto, LF Alexander, BC Allen… - Journal of the American …, 2017 - Elsevier
Despite the frequent statement that “most men die with prostate cancer, not of it,” the reality
is that prostate cancer is second only to lung cancer as a cause of death from malignancy in …

[HTML][HTML] The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer

C Arriaga-Canon, IA De La Rosa-Velázquez… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Prostate cancer is the most common cancer in men and the second leading cause of cancer-
related deaths. The most used biomarker to detect prostate cancer is Prostate Specific …